The recommended starting dose of Requip (Ropinirole) is 0.25 mg three times daily. The Requip (Ropinirole) dosage should then be gradually increased in weekly increments of 0.25 mg per dose to reach a daily dose of 1 mg three times daily. Based on individual patient response,Requip (Ropinirole) dosage may be increased by 0.5 to 1.0 mg per dose on a weekly basis to a maximum daily dose of 24 mg. When Requip (Ropinirole) is administered as adjunctive therapy with levodopa, the concurrent dose of levodopa may be decreased gradually by 20 percent on average. Requip (Ropinirole) will be available within the next few weeks for both initial therapy and adjunctive therapy with levodopa in 0.25 mg, 0.5 mg, 1 mg, 2 mg or 5 mg tablets. Requip (Ropinirole),unlike levodopa, does not need to be converted to dopamine and is immediately available to act on dopamine receptors. Clinical studies have shown that using Requip (Ropinirole) early in Parkinson's disease effectively controls motor symptoms, thereby delaying the use of levodopa.